These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21106906)

  • 1. Evidence that botulinum toxin receptors on epithelial cells and neuronal cells are not identical: implications for development of a non-neurotropic vaccine.
    Elias M; Al-Saleem F; Ancharski DM; Singh A; Nasser Z; Olson RM; Simpson LL
    J Pharmacol Exp Ther; 2011 Mar; 336(3):605-12. PubMed ID: 21106906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhalational poisoning by botulinum toxin and inhalation vaccination with its heavy-chain component.
    Park JB; Simpson LL
    Infect Immun; 2003 Mar; 71(3):1147-54. PubMed ID: 12595426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route.
    Ravichandran E; Al-Saleem FH; Ancharski DM; Elias MD; Singh AK; Shamim M; Gong Y; Simpson LL
    Infect Immun; 2007 Jun; 75(6):3043-54. PubMed ID: 17371853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding and transcytosis of botulinum neurotoxin by polarized human colon carcinoma cells.
    Maksymowych AB; Simpson LL
    J Biol Chem; 1998 Aug; 273(34):21950-7. PubMed ID: 9705335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of a membrane binding loop leads to engineering botulinum neurotoxin B with improved therapeutic efficacy.
    Yin L; Masuyer G; Zhang S; Zhang J; Miyashita SI; Burgin D; Lovelock L; Coker SF; Fu TM; Stenmark P; Dong M
    PLoS Biol; 2020 Mar; 18(3):e3000618. PubMed ID: 32182233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The C-terminal heavy-chain domain of botulinum neurotoxin a is not the only site that binds neurons, as the N-terminal heavy-chain domain also plays a very active role in toxin-cell binding and interactions.
    Ayyar BV; Aoki KR; Atassi MZ
    Infect Immun; 2015 Apr; 83(4):1465-76. PubMed ID: 25624352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the mechanisms that underlie absorption of botulinum toxin by the inhalation route.
    Al-Saleem FH; Ancharski DM; Joshi SG; Elias M; Singh A; Nasser Z; Simpson LL
    Infect Immun; 2012 Dec; 80(12):4133-42. PubMed ID: 22966044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid immune responses to a botulinum neurotoxin Hc subunit vaccine through in vivo targeting to antigen-presenting cells.
    White DM; Pellett S; Jensen MA; Tepp WH; Johnson EA; Arnason BG
    Infect Immun; 2011 Aug; 79(8):3388-96. PubMed ID: 21576339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Receptor-mediated transcytosis of botulinum neurotoxin A through intestinal cell monolayers.
    Couesnon A; Pereira Y; Popoff MR
    Cell Microbiol; 2008 Feb; 10(2):375-87. PubMed ID: 17900298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancing the protective immune response against botulism.
    Przedpelski A; Tepp WH; Kroken AR; Fu Z; Kim JJ; Johnson EA; Barbieri JT
    Infect Immun; 2013 Jul; 81(7):2638-44. PubMed ID: 23670557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Localization of the sites and characterization of the mechanisms by which anti-light chain antibodies neutralize the actions of the botulinum holotoxin.
    Takahashi T; Joshi SG; Al-Saleem F; Ancharski D; Singh A; Nasser Z; Simpson LL
    Vaccine; 2009 Apr; 27(19):2616-24. PubMed ID: 19428868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The life history of a botulinum toxin molecule.
    Simpson L
    Toxicon; 2013 Jun; 68():40-59. PubMed ID: 23518040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of systemic handling in the pathophysiologic actions of botulinum toxin.
    Al-Saleem FH; Ancharski DM; Ravichandran E; Joshi SG; Singh AK; Gong Y; Simpson LL
    J Pharmacol Exp Ther; 2008 Sep; 326(3):856-63. PubMed ID: 18539649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression, purification and characterization of the receptor-binding domain of botulinum neurotoxin serotype B as a vaccine candidate.
    Ben David A; Torgeman A; Barnea A; Zichel R
    Protein Expr Purif; 2015 Jun; 110():122-9. PubMed ID: 25727047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological characterisation and immunoprotective efficacy of functional domain antigens of botulinum neurotoxin serotype A.
    Liu FJ; Shi DY; Mao YY; Xiong XH; Lu JS; Pang XB; Dong XJ; Yang ZX; Yu YZ
    Vaccine; 2020 Mar; 38(14):2978-2983. PubMed ID: 32113807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant botulinum neurotoxin A heavy chain-based delivery vehicles for neuronal cell targeting.
    Ho M; Chang LH; Pires-Alves M; Thyagarajan B; Bloom JE; Gu Z; Aberle KK; Teymorian SA; Bannai Y; Johnson SC; McArdle JJ; Wilson BA
    Protein Eng Des Sel; 2011 Mar; 24(3):247-53. PubMed ID: 21051321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of a potential trivalent vaccine based on Hc fragments of botulinum toxins A, B, and E produced in a cell-free expression system.
    Zichel R; Mimran A; Keren A; Barnea A; Steinberger-Levy I; Marcus D; Turgeman A; Reuveny S
    Clin Vaccine Immunol; 2010 May; 17(5):784-92. PubMed ID: 20357058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Botulinum toxin as a carrier for oral vaccines.
    Simpson LL; Maksymowych AB; Kiyatkin N
    Cell Mol Life Sci; 1999 Oct; 56(1-2):47-61. PubMed ID: 11213260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deletion mutant comprising 198 residues of BoNT/A toxin receptor binding domain retained gt1b binding property but failed to induce protective antibody response in a mouse model.
    Singh MK; Gupta G; Boopathi M; Gupta P; Chauhan V; Tomar A; Singh L; Dhaked RK
    Protein Pept Lett; 2012 May; 19(5):530-7. PubMed ID: 22486648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Entry of Botulinum Neurotoxin Subtypes A1 and A2 into Neurons.
    Kroken AR; Blum FC; Zuverink M; Barbieri JT
    Infect Immun; 2017 Jan; 85(1):. PubMed ID: 27795365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.